Segment & Geographic Data
API & CSV Delivery
Orgenesis Inc's Business Segments
Orgenesis Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
2
Largest Segment
Therapies
Total Revenue
$ 0
Regions Reported
-
Annual Results
Revenue Share by Reportable Segment - FY2024
- Therapies0%
- Eliminations0%
Revenue by Reportable Segment - FY2024
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Therapies | $ 1 | - |
| Eliminations | $ 0 | - |
Revenue by Product & Service Category - FY2024
- Cell Process Development Services And Hospital Services0%
- Grant0%
- License Fees14%
Revenue by Product & Service Category - FY2024
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Cell Process Development Services And Hospital Services | $ 1 | - |
| Grant | $ 0 | - |
| License Fees | $ 0 | 14% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Orgenesis Inc
Orgenesis Inc is a Delaware-based biotechnology company that specializes in the development of advanced cell therapy technologies and regenerative medicines. The company primarily focuses on developing and commercializing autologous cell therapies that can be used for treating a range of diseases, including diabetes, liver disease, and other chronic illnesses.
Orgenesis is headquartered in Germantown, Maryland, with offices and subsidiaries in Israel and Belgium. The company was founded by Dr. Dorit Arad and Dr. Sarah Ferber in 2008, and has since expanded its research and development capabilities to become a leading innovator in the field of cell therapy.
The company's core technology is the Orgenesis Diabetes Cell Therapy (ODCT) platform, which uses a patient's own liver cells to produce insulin in response to glucose levels. This novel approach to diabetes treatment has shown promising results in preclinical studies and clinical trials, offering a potential cure for millions of people living with the disease.
In addition to its work in diabetes, Orgenesis is also developing cell therapies for other chronic diseases and conditions, such as liver disease, pancreatitis, and other autoimmune disorders. The company is also collaborating with leading academic and research institutions, such as the University of California, San Francisco, to advance the field of cell therapy and regenerative medicine.
Orgenesis has a strong intellectual property portfolio, with multiple patents and patent applications for its cell therapy technologies. The company is also committed to responsible and sustainable business practices, with a focus on environmental stewardship, ethical standards, and social responsibility.
Overall, Orgenesis Inc is a leading biotechnology company that is at the forefront of developing innovative, patient-centric solutions for chronic diseases and conditions using advanced cell therapy technologies.
Orgenesis is headquartered in Germantown, Maryland, with offices and subsidiaries in Israel and Belgium. The company was founded by Dr. Dorit Arad and Dr. Sarah Ferber in 2008, and has since expanded its research and development capabilities to become a leading innovator in the field of cell therapy.
The company's core technology is the Orgenesis Diabetes Cell Therapy (ODCT) platform, which uses a patient's own liver cells to produce insulin in response to glucose levels. This novel approach to diabetes treatment has shown promising results in preclinical studies and clinical trials, offering a potential cure for millions of people living with the disease.
In addition to its work in diabetes, Orgenesis is also developing cell therapies for other chronic diseases and conditions, such as liver disease, pancreatitis, and other autoimmune disorders. The company is also collaborating with leading academic and research institutions, such as the University of California, San Francisco, to advance the field of cell therapy and regenerative medicine.
Orgenesis has a strong intellectual property portfolio, with multiple patents and patent applications for its cell therapy technologies. The company is also committed to responsible and sustainable business practices, with a focus on environmental stewardship, ethical standards, and social responsibility.
Overall, Orgenesis Inc is a leading biotechnology company that is at the forefront of developing innovative, patient-centric solutions for chronic diseases and conditions using advanced cell therapy technologies.
Orgenesis Inc is an innovative biotechnology firm that specializes in the development of advanced cellular therapies aimed at treating a variety of diseases. The company operates through several key segments, each contributing to the overarching mission of enhancing patient care through the application of cutting-edge technologies and personalized medicine solutions. The primary segments of Orgenesis Inc include:
1. Contract Development and Manufacturing Organization (CDMO)
The CDMO segment is a crucial aspect of Orgenesis Incs operations. It provides comprehensive contract research and development services to biotechnology companies, enabling them to move from concept to market with their cellular therapies. This segment encompasses:
- Expertise in Cellular Therapy Development: Orgenesis offers its extensive knowledge in the development of various types of cellular therapies, including CAR-T cell therapies, gene therapies, and stem cell applications. This expertise aids clients in navigating the complex regulatory pathways associated with bringing new therapies to market.
- Manufacturing Services: The CDMO segment also encompasses manufacturing capabilities, allowing for the production of cellular therapies at scale. This includes optimizing production processes, ensuring quality control, and meeting regulatory compliance standards.
Point-of-Care Cell Therapy
The Point-of-Care segment represents a breakthrough approach in how cellular therapies can be delivered to patients. Key elements of this segment include:
- Personalized Cellular Therapies: Orgenesis leverages its proprietary technologies to create personalized cellular therapies tailored to the individual patients needs. This focus on personalized medicine enhances treatment effectiveness and patient outcomes.
- Point-of-Care Device: Central to this segment is the Point-of-Care Device, which allows for the on-site production of cellular therapies in a clinical setting. This device enables healthcare providers to generate therapies in close proximity to the patient, significantly reducing wait times for treatment.
- CellGROW Bioreactor System: The CellGROW bioreactor system is another pivotal technology developed by Orgenesis. This patented system facilitates the scalable production of large quantities of cells, whether for research purposes or for clinical applications. The versatility of the CellGROW system makes it applicable in various stages of therapy development, from preclinical studies to commercialization.
Immune Cell Therapy
Orgenesis Inc’s Immune Cell Therapy segment focuses specifically on the development of effective immunotherapies for treating cancer and autoimmune diseases. Important components include:
- CAR-T Cell Therapies: The development and commercialization of CAR-T cell therapies is a primary focus within this segment. These therapies involve engineering a patients own immune cells to better recognize and attack cancer cells, providing personalized and targeted treatment options.
- Novel Immunotherapy Approaches: In addition to CAR-T therapies, Orgenesis invests in research and development to create other forms of immune cell therapies designed to harness the bodys immune system against cancer and autoimmune conditions.
Products and Services
Orgenesis Inc offers an extensive portfolio of products and services that align with its segments, including:
1. CellGROW Bioreactor System: A patented platform for large-scale cell production, ensuring optimal conditions for cell growth and expansion, applicable for both research and clinical use.
2. Point-of-Care Device: A cutting-edge technology that simplifies and decentralizes the production of cellular therapies, enabling immediate access to personalized treatment options for patients.
3. Immune Cell Therapy Products: Development and provision of various immunotherapy products, including CAR-T cell therapies, specifically engineered to target cancer cells effectively and activate the immune response.
4. Contract Research and Development Services: Offering a suite of services targeting the research and development needs of biotechnology companies, including assistance in regulatory submissions, clinical trial design, and manufacturing processes.
Conclusion
Orgenesis Inc stands out in the biotechnology industry through its commitment to personalized medicine and innovative therapeutic solutions. Its comprehensive offerings span from contract development and manufacturing to groundbreaking point-of-care therapies, positioning the company as a leader in the development and production of cellular therapies aimed at addressing a multitude of complex diseases. The integration of advanced technologies and a focus on patient-centric care underscores Orgenesiss role as a transformative player in the field of biotechnology.
1. Contract Development and Manufacturing Organization (CDMO)
The CDMO segment is a crucial aspect of Orgenesis Incs operations. It provides comprehensive contract research and development services to biotechnology companies, enabling them to move from concept to market with their cellular therapies. This segment encompasses:
- Expertise in Cellular Therapy Development: Orgenesis offers its extensive knowledge in the development of various types of cellular therapies, including CAR-T cell therapies, gene therapies, and stem cell applications. This expertise aids clients in navigating the complex regulatory pathways associated with bringing new therapies to market.
- Manufacturing Services: The CDMO segment also encompasses manufacturing capabilities, allowing for the production of cellular therapies at scale. This includes optimizing production processes, ensuring quality control, and meeting regulatory compliance standards.
Point-of-Care Cell Therapy
The Point-of-Care segment represents a breakthrough approach in how cellular therapies can be delivered to patients. Key elements of this segment include:
- Personalized Cellular Therapies: Orgenesis leverages its proprietary technologies to create personalized cellular therapies tailored to the individual patients needs. This focus on personalized medicine enhances treatment effectiveness and patient outcomes.
- Point-of-Care Device: Central to this segment is the Point-of-Care Device, which allows for the on-site production of cellular therapies in a clinical setting. This device enables healthcare providers to generate therapies in close proximity to the patient, significantly reducing wait times for treatment.
- CellGROW Bioreactor System: The CellGROW bioreactor system is another pivotal technology developed by Orgenesis. This patented system facilitates the scalable production of large quantities of cells, whether for research purposes or for clinical applications. The versatility of the CellGROW system makes it applicable in various stages of therapy development, from preclinical studies to commercialization.
Immune Cell Therapy
Orgenesis Inc’s Immune Cell Therapy segment focuses specifically on the development of effective immunotherapies for treating cancer and autoimmune diseases. Important components include:
- CAR-T Cell Therapies: The development and commercialization of CAR-T cell therapies is a primary focus within this segment. These therapies involve engineering a patients own immune cells to better recognize and attack cancer cells, providing personalized and targeted treatment options.
- Novel Immunotherapy Approaches: In addition to CAR-T therapies, Orgenesis invests in research and development to create other forms of immune cell therapies designed to harness the bodys immune system against cancer and autoimmune conditions.
Products and Services
Orgenesis Inc offers an extensive portfolio of products and services that align with its segments, including:
1. CellGROW Bioreactor System: A patented platform for large-scale cell production, ensuring optimal conditions for cell growth and expansion, applicable for both research and clinical use.
2. Point-of-Care Device: A cutting-edge technology that simplifies and decentralizes the production of cellular therapies, enabling immediate access to personalized treatment options for patients.
3. Immune Cell Therapy Products: Development and provision of various immunotherapy products, including CAR-T cell therapies, specifically engineered to target cancer cells effectively and activate the immune response.
4. Contract Research and Development Services: Offering a suite of services targeting the research and development needs of biotechnology companies, including assistance in regulatory submissions, clinical trial design, and manufacturing processes.
Conclusion
Orgenesis Inc stands out in the biotechnology industry through its commitment to personalized medicine and innovative therapeutic solutions. Its comprehensive offerings span from contract development and manufacturing to groundbreaking point-of-care therapies, positioning the company as a leader in the development and production of cellular therapies aimed at addressing a multitude of complex diseases. The integration of advanced technologies and a focus on patient-centric care underscores Orgenesiss role as a transformative player in the field of biotechnology.